IP Verse

Eliglustat (Genz 112638) As Inhibitor Of Glucosylceramide Synthase For Use In A Method Of Treating Fabry'S Or Gaucher'S Disease, The Method Comprising Adjusting The Individual Therapeutical Dose To The P-450 Metabolism Of The Patient

Patent No. EP3133070 (titled "Eliglustat (Genz 112638) As Inhibitor Of Glucosylceramide Synthase For Use In A Method Of Treating Fabry'S Or Gaucher'S Disease, The Method Comprising Adjusting The Individual Therapeutical Dose To The P-450 Metabolism Of The Patient") was filed by Genzyme on Nov 24, 2010. The application was issued on Aug 14, 2019.

Patent Summary

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ACCORD HEALTHCAREMay 14, 2020BRAND MURRAY FULLER
HETERO LABS LIMITEDMay 14, 2020ZBM PATENTS APS
TEVA PHARMACEUTICAL INDUSTRIES LTDMay 13, 2020D YOUNG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP3133070

GENZYME
Application Number
EP16175117A
Filing Date
Nov 24, 2010
Status
Revoked
May 19, 2025
Publication Date
Aug 14, 2019
External Links
Slate, Register , Google Patents